Escaping Death: Naloxone\u27s Chemical Nature and Potential to Combat the Opioid Epidemic by Miller, Abigale
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Honors Theses, University of Nebraska-Lincoln Honors Program
Spring 3-1-2019
Escaping Death: Naloxone's Chemical Nature and
Potential to Combat the Opioid Epidemic
Abigale Miller
University of Nebraska - Lincoln
Follow this and additional works at: https://digitalcommons.unl.edu/honorstheses
Part of the Biochemistry Commons, Bioethics and Medical Ethics Commons, Biology
Commons, Medical Humanities Commons, Medicine and Health Commons, and the Politics and
Social Change Commons
This Thesis is brought to you for free and open access by the Honors Program at DigitalCommons@University of Nebraska - Lincoln. It has been
accepted for inclusion in Honors Theses, University of Nebraska-Lincoln by an authorized administrator of DigitalCommons@University of Nebraska
- Lincoln.
Miller, Abigale, "Escaping Death: Naloxone's Chemical Nature and Potential to Combat the Opioid Epidemic" (2019). Honors Theses,
University of Nebraska-Lincoln. 102.
https://digitalcommons.unl.edu/honorstheses/102
  
 
Escaping Death: 
 Naloxone’s Chemical Nature and Potential to Combat the Opioid Epidemic  
 
An Undergraduate Honor Thesis 
Submitted in Partial fulfillment of 
University Honors Program Requirements 
University of Nebraska -Lincoln  
 
By 
Abigale Miller, BS 
Biological Sciences 
College of Arts and Sciences  
 
 
 
March 1st, 2019 
 
 
 
 
Faculty Mentors: 
Dr. Chris McCune, PhD, Department of Chemistry 
Dr. Lisa Mansur, M.D, Department of Gerontology 
 
Other Contributors: 
Dr. Lisa Kort- Butler, PhD, Department of Sociology 
Scott Schrage, Office of University Communications 
2 
 
 
Contents 
Abstract ........................................................................................................................................... 3 
Introduction ..................................................................................................................................... 4 
A Society of Addiction ................................................................................................................... 8 
Naloxone’s Chemical Nature ........................................................................................................ 27 
Utilization and Accessibility of Naloxone .................................................................................... 53 
Conclusion .................................................................................................................................... 75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
Abstract  
 
  Naloxone is a life-saving drug with the ability to reverse an opioid overdose. As the 
opioid epidemic’s death toll rises, we can turn to Naloxone as a tool to combat the crisis. The 
epidemic, born of corruption, has a wide reach among the people of the United States, with 
especially firm grasps on middle-aged people, sufferers of chronic pain, white Americans and 
those living in the eastern portion of the country. Naloxone’s elegant design saves lives by 
effectively competing for a position on an opioid biding receptor in the brain to almost instantly 
end an overdose and restore normal breathing. It can be effectively administered through simple 
mechanisms, so that the lay person is able to save a life. Efforts to increase access across the 
country have spanned community programs and state legislatures. Increasing access to Naloxone 
can save more lives and allow the dug to better combat the opioid epidemic.  
 
Key Words: Naloxone, Narcan ®, Opioid, Opioid Epidemic, Opioid Crisis, Addiction, Death 
Rate, and OxyContin.  
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Escaping Death: 
 Naloxone’s Chemical Nature and Potential to Combat the Opioid Epidemic  
 
Introduction 
 
A few minutes after midnight a dark-haired woman, Liz, takes her the first of her last 
breaths. She is lying across the dark gray sheets of her full-sized bed. Her tired body is laboring 
to draw in the cool and plentiful air around her, and a low raspy note is escaping her pale lips. 
Her face and body are worn from years of long hours on the assembly line spent sorting the 
deformed pieces pork from those that met her approval. Not to mention the period she surfed 
couches during the recession, only to find her way back to another grueling job as a custodian for 
the local airport. How did she end up here?  
She cannot know that 122 miles to the east, in Huntington, West Virginia, a 19-year-old 
boy is struggling for air, as well. While she was alone, lying nearly still on the bed, Josh lay 
slumped in the corner of the couch in his parent’s basement. His head lay crooked, nearly sliding 
off the edge of the couch – a position that any person would have quickly shifted out of. But Josh 
lay still except for the slow and shallow movement of his chest. His friend Caleb looked around 
at the neatly painted crown molding that ran along the ceiling. The house was otherwise empty, 
Josh’s parents out of town for a funeral. Caleb watched Josh breathe in, slowly realizing what 
was happening. 
******* 
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Liz was overjoyed when she received a prescription for oxycodone back in 2004, having 
never felt pain like this before. It was not a surprise, she had felt the pain in her back slowly 
growing as the hours bent over working, lifting things she shouldn’t have, and that tumble she 
took on the ice a few years ago had taken their toll on her body. The oxycodone made her feel 
amazing, like she was taking her life back from the pain. Over time the dosage increased, and she 
eventually could not afford the price tag of her pain-free life. To save a few bucks, she began to 
buy oxy and hydro from a friend. The price tag continued to drop when she made the leap to 
heroin. 
Josh never made that jump, preferring the oxycontin he could buy from a friend. Why did 
he buy it in the first place? He was probably dared to do it, or maybe he was just curious. He 
could no longer remember. It didn’t really matter anyway. He was here in this moment, a 
moment he thought he would never see.  
Caleb was in anguish, sure that something had gone wrong but unsure what to do. He was 
scared that he would be arrested, that his parents would find out, but mostly that his friend would 
die. He picked up Josh’s cell phone and dialed 911, frantically telling the operator where he was 
but refusing to say anything else before ending the call and running as fast as he could, leaving 
the door open on his way out.  
 They were are both alone, Liz and Josh, both counting down the few breaths they have 
left.  
All of the sudden the world around Josh is moving so fast, not in a chaotic way but 
organized, methodical. The EMTs have arrived and are assessing the situation. They note 
hypoventilation, cyanosis, and the “death rattle” in his throat. They would have noted the same if 
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they stood next to Liz. They move Josh onto the carpet and the taller of the two EMTs violently 
rubbed Josh’s sternum with his knuckles. Nothing happened. The EMT looked at his partner and 
administered Naloxone. One puff of spray into his left nostril. They waited a moment and looked 
for any signs from Josh. They spoke to him. “Hey buddy, you gotta wake up now. Come on, take 
a breath for me.” After a few minutes, another puff went up his right nostril. Again, they called 
out to him and continued to forcibly rub his sternum. This time, something happened.  
The blue color in Josh’s lips slowly returned to a youthful pink, his breaths becoming 
deeper and deeper – as Liz’s stopped. His eyes fluttered open to see two new faces staring down 
at him, he escaped the grasp of death. 
Liz would never open her eyes again; her life was over. The drug that had returned her 
life to her had also taken it away.  
The story you have heard is not an uncommon one. Opioid overdoses have led to deaths 
of friends and family across the country – so much so that the mortality rate by unintentional 
injury has increased drastically in the United States. As a result of the opioid epidemic, 
unintentional injury – including overdose – jumped from the fourth-leading cause of death in 
2015 to the third-leading cause in 2016 (Kockanek et. al,  2017). As you can see in Figure 1, the 
number of opioid overdoses has skyrocketed since the 2013, rising from three deaths per 100,000 
in 2000 to a staggering 13 deaths per 100,000 in 2016. While this number may seem 
insignificant, it represents a quadrupling of deaths from opioid overdoses. Furthermore, the death 
rate caused by synthetic opioids such as fentanyl has increased drastically in just three years 
(Opioid data analysis | drug overdose | CDC injury center, 2017). Overall, deaths from opioid 
overdose have risen by 113% in just the past 10 years (Weaver, Palombi, & Bastianelli, 2018).  
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  Like any subject or issue facing the United States, the opioid epidemic is not one-sided. 
There are many factors that have caused the epidemic and tightened its grasp on the country. 
However, we are not defenseless against this battle and are armed with treatments like Naloxone. 
This miraculous drug can reverse an overdose, retuning people from the edge of death. We will 
focus on three aspects of Naloxone’s role in the opioid epidemic: the sociology behind the 
epidemic and the people who are most at risk of an opioid overdose; the chemical nature of 
Naloxone, how the treatment is synthesized and the mechanism by which it functions; and the 
public policy and legislation that is working to bring Naloxone into the hands of the people. 
These topics weave together to form wholesome and vibrant image of the opioid epidemic.  
Figure 1. Opioid Overdose Deaths 2000-2016 (CDC, 2017) 
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A Society of Addiction 
 
 The current opioid epidemic is in many ways a 
recurrence of previous opioid and drug crises that 
have plagued the people of the United States. The first  
wave swept the country in the late nineteenth century. 
Opioid consumption increased by 538% until it finally 
reached its peak midway through the 1890s. The crisis 
slowly dwindled into the 1900s, the rate of people 
suffering from opioid addiction fell from 4.59 per 
1,000 people at the height of the crisis 1.97 opioid- 
addicted people per 1,000 in 1920. This crisis was 
largely attributed to self- medication.  It was not 
uncommon for mothers to give their children and 
themselves opium tinctures (a syrup in which a 
medication was dissolved in alcohol)  and for 
Soldiers to use opium and morphine to treat diarrhea and to manage their pain. Many Chinese 
immigrants also smoked Opium, a practice that was adapted by many native people and spread 
across the country. The “poster child” of this opioid crisis was a middle-aged white woman 
suffering from iatrogenic morphine addiction as a result of a chronic illness. A similar picture is 
found 130 years later as opioids have taken hold of this country once again (Kolodny et al., 
2015).  
 Physicians were limited in the number and type of analgesic drugs available in the late 
nineteenth century and they often prescribed opioids for pain management, despite alternative 
Figure 2. Advertisements for a cough 
medication that contained heroin where 
common in the 1800’s and early 1900’s 
(Heroin's History). 
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drugs and therapies availiable physicians continue to rely heavily on opioids for pain 
management. This trend in prescribing is rooted in the influence of the pharmaceutical industry 
and poorly written primary literature. In 1986 a paper describing the treatment of thirty- eight 
chronic pain patients falsely found that Opioids could be safely prescribed without any long-term 
consequences. The paper was widely cited for the expansion of treatment of non-cancer chronic 
pain with opioids despite the poor evidence it provided (Kolodny et al., 2015).  
Opioid use was gradually increasing through the 80’s but rates began to skyrocket after 
the advent of OxyContin, an extended release formula of oxycodone produced by Perdue 
Pharma. The company immediately began advocating for the use of oxycontin to treat pain but 
primarily chronic non-cancer pain.  In just over six years Perdue Pharma funded over 20,000 
pain-related education programs and launched a movement to increase the prescription rates of 
opioids. A major part of this campaign included funding for the American Pain Society, the 
American Academy of Pain Medicine, the Federation of State Medical Boards, and Joint 
Commission (which accredits hospitals and health care facilities) and many patient advocacy 
groups. As a result, these groups advocated for the aggressive treatment of pain and improved 
pain management, undoubtedly through the use of OxyContin. The efforts of one such group, the 
American Pain Society created the “Pain is the Fifth Vital Sign” campaign, a practice that is still 
used in hospitals and taught to medical professionals across the country. This movement 
encouraged professionals to monitor patient’s pain levels as thoroughly as blood pressure, heart 
rate, respiratory rate and, blood oxygen saturation using a scale of 0 to 10. This campaign 
became extremely popular after the Joint Commission and Veterans’ Affairs health system both 
incorporated the campaign into their own practice (Kolodny et al., 2015). 
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Despite the efforts of Perdue Pharma many physicians remained reluctant to prescribe 
opioids as a long term to treatment for chronic pain because of their concerns about addiction. 
This so called “opiophobia” was addressed by opioid manufacturers use of paid physician 
advocates. These physicians published papers and gave lectures targeted to the medical 
community and their fellow practitioners. These lectures claimed that doctors confused addiction 
with what they called “physical dependence”. They argued that addiction was rare and unlikely  
and that “physical dependence” was not clinically relevant. Theses lectures included data from 
studies with methodological flaws claiming the risk of opioid addiction was less than one 
percent. This campaign also exaggerated the benefits of long-term opioid use, despite the fact 
that quality studies on the effects and safety of opioid for long-term use had not been done. The 
use of opioids to treat acute pain in hospitals also increased over this period. Between 2009 and 
2010 a survey found that physicians prescribed opioids in over 50% of the 1.14 million 
nonsurgical hospitals stays, and many times in high doses. The “Pain is the Fifth Vital Sign” 
campaign also lead to mandatory patient satisfaction surveys. These included questions asking if 
 
 
 
Figure 3. Opioid sales, 
unintentional overdose deaths, 
and opioid addiction treatment 
admissions from 1999-2010. 
(Kolodny et al., 2015) 
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hospital staff did “everything they could do to help your pain”. The introduction of these surveys 
is noteworthy as they are associated with increased use of opioids in hospitals. Unsurprisingly, as 
the amount of opioid prescriptions increased so did the number of opioid related death and 
opioid addiction treatment, Figure 3 (Kolodny et al., 2015). Naloxone came into the play when it 
was first synthesized in 1960 by Jack Fishman and was investigated further by Harold Blumberg, 
at the New York City Medical College. Naloxone was approved by the Food and Drug 
Administration in 1971 (Green & Doe- Simkens, 2016). Even though Naloxone had been 
available for nearly fifty years, only recently has the medicine been utilized properly to reduce 
death rates. 
One common misconception about people who inappropriately use opioids, including 
heroin, is they that began using the drug for recreational use. The efforts of many states to reduce 
opioid use and abuse have targeted people who use the drug solely for recreational purposes and 
Figure 4. The rates of first- time nonmedical opioid use (Kolodny et al., 2015). 
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does not address people who have or had a prescription for the drug. By doing this they are 
ignoring the high morbidity and mortality rates of people who use opioids for medical purposes, 
typically chronic pain. The incidence of nonmedical use of opioids reached a peak in 2002 with 
2.7 million new nonmedical users, this rate has since dropped by over half to 1.8 million 
nonmedical users. Despite this fact, the number of opioid users, overdoses and addiction 
treatment admissions have continued to increase. This highlights the high percentage of opioid 
users who use these drugs for medical purposes. To further illustrate this point, of the 254 
unintentional overdose deaths in Utah over 92% were from people who had prescriptions for 
opioids.  Figure 2 above illustrates the increasing consequences of opioid abuse, being death and 
a higher demand for treatment, despite the decrease in nonmedical use displayed in Figure 4 
(Kolodny et al., 2015). Efforts to find alternative and non-pharmalogical methods of pain 
management can decrease the number of opioid prescriptions and prevent future overdoses.   
There is also a relationship between opioid use and suicide. People suffering from 
chronic pain, which is typically treated with opioids, are more likely to commit suicide. One 
study revealed that of the 123,181 suicide decedents for which they analyzed data 8.8% had 
chronic pain. More importantly, they observed an increase of 2.8% in suicide rates of people 
with chronic pain between the years 2003 and 2014. This mirrors the trends in the opioid 
epidemic (Petrosky et al., 2018). When looking at the total number of suicides, firearm use is the 
most common method and poisoning which includes purposeful opioid overdose is the third 
most common method, Figure 5 (Suicide method statistics in the US.).   
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The researchers also suspect that the percentage of suicide decedents with chronic pain is 
higher than discovered because of a flawed reporting system.  They conclude that chronic pain 
places an individual at a higher risk for both fatal and nonfatal suicide attempts (Petrosky et al., 
2018). An article in the New England Journal of Medicine proposes that suicide accounts for 
about 20-30% of all opioid overdoses, a percentage much higher than previously thought. 
(Oquendo & Volkow, 2018). It is important to note that people with chronic pain oftentimes 
have depression and anxiety as a result of the social and physiological effects of pain. The higher 
incidence of mental illness has a direct relationship to the rate of suicide among people with 
chronic pain (IIgen, 2018).  
There are two opposing hypotheses explaining the effects of opioids on individuals with 
chronic pain. The first is that large quantities of opioids are fatal, and suicide prevention 
Figure 5. Methods by which suicide is committed in the United States. 81% of the 
poisonings involve the ingestions of drugs including opioids and the remaining 15% involve 
inhaling toxic gas (Suicide method statistics in the US.).  
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literature has shown that access to fatal means increases an individual’s risk of suicide. Thus, 
individuals with a prescription for an opioid or who can obtain opioids illegally are at higher 
risk. One study found that U.S veterans who were prescribed higher doses of opioids were more 
likely to commit suicide. According to the first hypothesis the access these people had to high 
dosages of opioids put them at risk to commit suicide by providing the means to do so. The 
second hypothesis suggests that opioids are used as a coping mechanism for chronic pain. 
Individuals may use opioids to escape their pain and reality that follows in the wake of the pain, 
this behavior may lead to heroin use or an unintentional overdose as they increase the dose of 
opioids to obtain their desired escape. It is also important to note that of the suicide decedents 
with chronic pain 51.9% had opioids in their system shortly after the time of death which could 
be a result of this behavior or the cause of the suicide. The high risk of people with chronic pain 
for suicide risks suggests that general suicide prevention strategies should be applied to this 
population in an effort to prevent harm. This can include the monitoring of the mental health and 
wellbeing of at risk patients as they are asked to divulge any suicidal thoughts or actions they 
have experienced to heath care professionals (IIgen, 2018).  
As the use of opioids has increased, so have the rates of heroin use. After receiving a 
prescription and becoming addicted to opioids many people turn to illegal distributers to obtain 
hydrocodone, oxycodone, oxycontin, or other prescription medications when physicians refuse to 
continue to prescribe or increase the dosage or upon the realization that the cost is much less on 
the street than it is in the pharmacy. While illegal opioids are cheaper, heroin offers another 
opportunity to save money as opioids are much more expensive to purchase illegally than heroin. 
As a result, many people begin using heroin as an alternative to prescription opioids. 
Furthermore, heroin has also become easier to obtain because of the increased regulations placed  
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on opioids to prevent its illegal sale and “doctor shopping”. When these strict regulations were 
placed on opioids it became more difficult for dealers to obtain the pills and lead to an increased 
price that drove people to heroin. Heroin also does not require as large of a dose compared to 
prescription pills for users to obtain their desired high.  
Kent Kerley and his colleges compiled a collection of narratives from women in a 
treatment facility in Texas as they described their experiences with opioids. The majority 
described suffering from chronic pain from diseases or after injury that lead to the abuse of 
prescription opioid and later heroin. Some women had been prescribed opioids to treat conditions 
such as fibromyalgia and others after undergoing invasive fertility treatments. One woman 
described the beginning of her use “It was a prescription. I had to have a pretty major surgery, 
and was given them for about five months and of course when they quit giving them to me I 
started buying them” (Kerley, Webb, & Griffin, 2018). By decreasing the inappropriate opioid 
prescriptions and providing better and more accessible addiction treatment the rates of heroin use 
will also fall as the opioid epidemic declines (Kerley et al., 2018).  
                                                               
 
Figure 6. Opioid overdose death from 1999- 2016 based on age group.  
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The age demographic of the opioid epidemic paints a picture of a drug that is affecting all 
generations with the heaviest toll falling on middle aged Americans. Nonmedical opioid use is  
most common in the younger generation, with the highest rates of opioid use found between ages 
15 and 24. The highest rate of opioid overdose was found to be among middle aged people, 
individuals between 45 and 54 years old (Figure 6). Furthermore, the age group that has 
experienced the greatest increase in overdose mortality between the years 1999 and 2016 are 
those who are  between 55 and 64. While this may not make sense, as addicts are commonly 
thought to be young,  it is not surprising when you consider the effects of chronic pain. Middle-
aged people and the elderly are much more likely to experience chronic pain (as well as acute 
pain) and to visit doctors seeking to resolve this common issue. As a cohort, they are more likely 
to receive prescription opioids (Kolodny et al., 2015).  
A study focusing on the risk factors involved with the development of opioid addiction 
among people in receiving outpatient therapy found that middle- aged and elderly people were 
more likely to develop an addiction to opioids. They also examined other factors such as the 
presence of depression and if the pain was affecting the patient’s daily lives (Boscarino et al., 
2010). While these factors may seem to be independent of age and are also found in younger 
people, they are a very common factor among aging individuals. It is important to keep in mind 
that cohorts behave in a specific way and move through time together. The baby boomers who 
previously held the place in the 45-54 spot have been replaced by the next generation and so on 
and so forth. This crisis is not entirely driven by the difficulties of aging but also by a generation 
that is more likely to be addicted to opioid (Fox, 2017). The baby boomers (1946-1964) lived in 
era of free love, civil rights,  political protest,  and socially acceptable drug usage, these 
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behaviors and ideals can follow the cohort through time.  The patterns we observe among 
different age groups are not the only trends when it comes to the opioid epidemic.   
The opioid epidemic has reached individuals in every class, racial, and ethnic group in 
this country but there are two groups that have been ravaged by the epidemic. As you can see in 
Figure 7, Whites and Native Americans have higher opioid related deaths than any other ethnic 
group (Okie, 2010). The high rates in opioid related deaths and opioid addiction among Native 
Americans can be traced back to the limited healthcare and the scarred mental health of the 
population. This population faces a physician and health care shortage more substantial and 
debilitating than any other group in this country. Usually there is only one facility (hospital, 
clinic, or other source of health care) for a large community of people and individuals living in 
the surrounding areas. Many times, these people have to travel hours to see a physician for a 
routine appointment, prenatal care, or if they have concerns regarding mental health. This 
process is further exacerbated because of the extreme poverty that many of Native Americans 
face. This group of people also suffer from high rates of mental illness, domestic violence and  
Figure 7. Opioid related death rates among various races (Dubb, 2017) 
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traumatic events and have little or no resources for their benefit. These traumas have created 
communities who are vulnerable to addiction and alcoholism. This effect is reflected in the 
statistics (Figure 7) that display the desperate and tragic situation these people face (Rieckmann 
et al., 2012).  
We have also observed high opioid related mortality among white people. Unlike the 
untold stories of Native Americans and other minorities, opioid related death of white people is 
often presented to the public after manipulation by the media. There are two opposing messages 
that the media delivers about opioid overdose and use among the population of white people in 
the US. Many media portrayals of instances of overdose mortality show middle class families 
working together to assist a loved one in their journey to fight their addiction. Images used often 
show sunny and pleasant homes and the new and state-of-the-art facilities where people can 
receive treatment (Figure 8). A very different circumstance is portrayed for lower class white 
individuals. The addiction and instances of overdose of lower-class individuals are not addressed 
using the “Gentler War on Drugs” method that their wealthier counterparts are afforded. Media 
portrayals of these people often depict bleak situations: mothers losing custody of their children, 
people who lied to their friends and family, and images of police officers searching through 
Figure 8. The image above was found in a local news article on the opioid overdose in a low-income town in 
West Virginia entitled “West Virginia City has 27 heroin overdoses in 4 hours”. Whereas the image on the 
bottom displays a middle-class military family after before their son died from an opioid overdose entitled 
“No Family is safe from opioids” (March, 2016) and (Winnefeld, 2017). 
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property (Figure 8). Lower class white individuals are not treated as a person with a disease but 
are thought of as criminals. They are punished for their actions and are enrolled in mandatory 
drug treatment regulated by the criminal justice system. This process that many cannot afford is a 
combination of the price to attend mandatory meetings with probation officers, finding adequate 
travel to what may be a two- or three-hour drive, and the time off work leading to the potential 
loss of their job is a financial barrier that many people cannot overcome. This issue is especially 
prevalent in rural areas where the population is largely composed of lower-class white 
individuals. While middle- and upper-class users are viewed as sick and in need of help low-
class and minorities are thought of as criminals and are treated as such (Wakeman & Rich, 
2018).  
Figure 9. Opioid related death rates by region of the United States. This tables shows an 
increase in opioid related deaths across the country, with especially high rates of change in 
the Northeast region (Rudd et al., 2016).  
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Rates of opioid death and use vary across the country, currently the northeast region has 
the highest rates of opioid related deaths.. Figures 9 and 10 display the changes in the rate of 
opioid related deaths by region and state. This data shows that the western area of the United 
States (including California, Arizona, and Utah) initially had the highest rates of opioid related 
deaths, but it shifted to northeastern United States. You can see in Figure 9 the difference is 
opioid related death rates in each region and Figure 10 visually illustrates this shift along with 
the overall increase in opioid use. The effects of opioid he addiction are extremely prevalent in 
states including West Virginia, Pennsylvania, and Kentucky (Rudd et al., 2016). This trend can 
be explained in part by the number of opioids that are prescribed in these regions.  The more 
opioids prescriptions the more addiction present in within the region. Higher rates of opioids 
prescribing follow general pattern of the higher than average health care spending and higher 
Medicare spending. Longer hospitals stay and unnecessary procedures cause needless pain which 
is treated with opioids, starts the addiction process, but also generates a profit . Attention must be 
drawn to the health care systems in these communities, where patient centered, and value-based 
care is sacrificed for profit (Fisher, Bynum, & Skinner, 2009).  
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Figure 10. Shifts in opioid overdose rates by state. Between 1999 and 2016 the trends moved from being the 
highest in the western region to the northeast. Also note the changes in the legends, the higher death rates are 
indicative of the overall increase in opioid deaths (Drug overdose mortality by state.2018). 
22 
 
 
 This careless practice of heath care is not an isolated to the northeast, communities across 
the country face the same patterns of inappropriate medical actions. An overarching case study 
of the health system in parts of Texas after investigation revealed an extremely high health care 
spending by the state. By becoming aware and fixing the issue the cost of health care in the area 
dropped and the quality of care increased (Gawande, 2009). The state of Texas also saw a 
relative decrease in the rate of opioid overdose related deaths. Suggesting that general 
improvement to the health care system may also cause a decrease in the rates of opioid related 
deaths (Drug overdose mortality by state.2018).  
 
 
 
 
 
Figure 11. Shows the results of several questions regarding the opioid epidemic. Including public opinion 
on stigma, concern for the epidemic and parties held responsible for stopping the epidemic. Data from: 
(Blendon & Benson, 2018). 
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The use of opioids has nearly quadrupled since 1999, as this trend has shifted so has  
mindset and opinion of the American public. Public surveys from organizations including the 
Keiser Family Foundation and the Pew Research Center were combined and analyzed to look 
into the opinions of the American public. The majority of people, 53%, believe the opioid 
epidemic to be a major problem but not a national emergency and in a list of national health 
concerns the epidemic was only ranked fifth. The majority of people, 63%, are aware the use of 
opioids and that effects have been increasing, while the remaining 37% believe that the epidemic 
has remained in the same proportions or has decreased. Most people agree that the medical and 
mental health community is responsible for fighting the epidemic but 33% believe that the issue 
is to be blamed chiefly on practitioners who inappropriately prescribed pain killers. These people 
failed to acknowledge the roles of pharmaceutical companies and their campaigns including the 
“Pain is the Fifth Vital Sign” movement in the opioid epidemic. The majority of people believe 
that addiction is a condition and that these people should be treated, 65%, rather than 
Figure 11 Continued.. Data from: (Blendon & Benson, 2018). 
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incarcerated, 28%. This circles back to the opinion that it is the responsibility of the health care 
system to fight the battle against the opioid epidemic. It is unsurprising that most people have 
had experience with opioids, 64% of people have been prescribed opioids and 49% of people say 
that they know someone who suffers from opioid addiction. Despite the desire for treatment 
opposed to criminalization, only 45% of people favored the idea of allowing people to obtain 
Naloxone from pharmacists negating the need of a physician’s prescription for the drug. These 
people favor a system where the consequences of opioid use will continue to be death rather than 
a second chance. Lastly, only a third of people believed that reducing the stigma around opioid 
addiction would be helpful to reducing the effects of the epidemic (Blendon & Benson, 2018).  
 Despite the opinion of the public, the stigma surrounding opioid use has been slowing the 
progress made to decrease the consequences of the epidemic on the United States. This stigma is 
affecting the degree to which treatment is availiable and the way in which people receive 
treatment. There are four common issues and ideas commonly found among Americans that are a 
driving force of the stigma. These ideas include the common misconception that addiction is 
willful choice opposed to a disease, notions to separate addiction treatment from the medical 
system (and thus further sink into the criminal justice system), the language associated with 
addiction and addiction treatment found within the criminal justice system, and the fact that the 
criminal justice system does not incorporate medical judgement during prosecution. For instance, 
the language used when refereeing Naloxone often portrays the drug as a secondary measure and 
nonessential even though it is a life-saving drug (Wakeman & Rich, 2018). For instance, the 
EpiPen is a dug that fundamentally accomplished the same goal as Naloxone, it saves a life by 
restoring an individual’s breathing. Yet, because Naloxone is treating addiction and an EpiPen 
are treating allergies they are thought of as complete opposites.  
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 Opioid users receive their medical treatment as criminals and not as a people, because of 
stigma. For this reason, people in prison or who have previously in prison have extremely high 
rates of opioid overdose. Furthermore, the lack of addiction treatment within this group of people 
that need quality treatment is astounding. The risk of death caused by drug overdose is increased 
129 times after an individual is released from prison, yet this population remains with little to no 
access to care. Treatment programs have shown to be successful in reducing the amount of 
opioid related deaths after release from prison. One program in the U.K. reduced the all-cause 
mortality by 75% and the reduced the number of fatal overdoses by 85% (Wakeman & Rich, 
2018). 
Figure 12. Images of advertisement campaign from Michigan with a goal to spread 
the awareness of the dangers of opioid addiction  (Advertising: The tantalizing works 
of Paul Forsyth, Cade Buckus, and Rick Iseppi of Michigan, USA.2018). 
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There are many options to work to reduce the stigma surrounding opioid addiction which 
may cause a shift in opinion favoring a medical approach to addiction and addiction treatment. 
These include public education measures and increasing the privacy associated with treatments. 
Figure 12 is an example of an advertisement campaign in Michigan with the goal of spreading 
awareness of the risks of opioids addiction. Currently opioid addiction is treated by facilities that 
specialize addiction treatment, this means that individuals in treatment are easily labeled as 
addicts. Suggestions for improvement include addiction treatment in primary care settings and 
allowing the distribution of addiction treatment medications to occur at pharmacies rather than at 
addiction treatment facilities. This will increase both the privacy of individuals in treatment as 
people will not be able to tell if they are receiving addiction treatment or another treatment and 
increase the availability of addiction treatment (Wakeman & Rich, 2018).  
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Naloxone’s Chemical Nature 
 
Like any molecule, the structure of Naloxone is directly related to its function. Just as the 
shape and molecular make-up of the protein hemoglobin makes it conducive to transport oxygen; 
it is naloxone’s structure that allows this molecule to interfere with the opioid’s action in the 
brain and disrupt an overdose. The structure of Naloxone is very similar to that of the common 
opioid morphine. Differing only by a hydroxyl group a simple combination of one oxygen and 
one hydrogen (OH) and a double bond between carbon atoms and allyl group (two doubly 
bounded carbon atoms attached to a single bonded carbon). Naloxone is a multiring molecule, 
containing a tetrahydrofuran ring, phenol, a cyclohexane and bicyclic ring as seen in Figure 13. 
The ketone is an especially reactive part of the molecule and must be taken under careful 
consideration during synthesis of the molecule (Werner et al., 2012). The similarities between 
Naloxone and morphine allow them to interact with the biochemistry of the brain in a similar 
way.  
 
Figure 13. Comparing structures of opioids and opioid antagonists.  (Werner et al., 2012). To 
read the images substitute the structures into the location of R.  
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Chemical Synthesis  
 
                Naloxone is most commonly 
synthesized using semi-synthesis techniques.  
Semi-synthesis is a method that allows 
complicated molecules to be created by 
modifying an existing and chemically similar 
molecule. Many times, this starting molecule 
is a naturally occurring molecule, something 
that is made by a plant for instance. This also 
makes it easier to make large amounts of a 
molecule as the staring molecule can be 
collected in large quantities. This process is 
analogous to buying a birthday cake and 
changing the frosting to your friend’s name 
instead of baking them a cake from scratch.  
Many drugs are created using semi-
synthesis. These include the over fifty antibiotics that are created through semisynthetic routes, 
such as, tetracycline, clarithromycin and ceftazidime (Wright, Seiple, & Myers, 2014).  One 
drug, Taxol, was an important step forward for semi-synthesis. Taxol is a chemotherapy 
medication commonly used to treat metastatic breast and ovarian cancer, along with other 
cancers such as lung cancer, head and neck cancer, and cervical cancer. Taxol works by 
preventing cell proliferation or division during mitosis. The drug does this by strengthening the 
microtubules found in the cell. These structures are utilized during mitosis to separate the 
Figure 14. This image shows an epithelial cell in 
metaphase, one of the stages of mitosis. The red 
structures are the microtubules attached to the 
chromosomes (blue). When Taxol is present in the 
cell this process is prevented, and thus the cell 
cannot replicate. (Epithelial cell in metaphase, 2013)  
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chromosomes onto opposite hemispheres of the cell. By strengthening the microtubules this 
separation process cannot occur. More specifically, the drug prevents the depolymerization of 
microtubules in the cell preventing them from reforming into spindle fibers, the structures that 
act as ropes in the process of separating chromosomes. You can see normal spindle fiber in 
action in Figure 14, this process is prevented by Taxol. Taxol is naturally produced by the pacific 
yew tree, Taxus brevifolia, and it is found in small quantities in the bark of the tree. So that just 
one kilogram of Taxol would require the harvesting of 2,000 to 3,000 trees (Jennewein & 
Croteau, 2001). Scientists turned to another option to create Taxol, semi-synthesis. After the 
discovery of a very similar molecule, 10-decacetylbaccatin III (Figure 15) was found in the much 
more available needles of the English Yew tree scientists developed an important protocol to 
create the life-saving drug. With careful consideration for the stereochemistry of the drug Taxol 
was successfully created using semi-synthesis (Suffness, 1995). The original protocol created by 
Robert Holton and his staff is still used to commercially synthesize the anti-cancer drug (Holton 
et al., 1993). 
  
Figure 15. Taxol’s structure is seen 
at the top of this figures and the 
precursor used in semi-synthesis 
can be found in the bottom left 
(Suffness, 1995). 
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Utilizing a semi-synthesis protocol to create Naloxone is a much more efficient and 
environmentally conscious alternative to directly synthesizing the drug. Furthermore, the small 
variations in the protocol can be utilized to create various other opioid antagonists, increasing the 
versatility of the process 
and allowing for the 
creation of other treatments. 
These other drugs include 
naltrexone (commonly used 
as a treatment for alcoholism), 
and nalbuphine (Werner et al., 2012). Unlike many other opioid antagonists, including 
naltrexone, the synthesis of Naloxone is constrained by semi-synthesis as N-demethylation can 
create issues for the synthesis, even though semi-synthesis is more efficient the process is still 
not simple and without complication.  N-demethylation simply put, involves replacement of the 
methyl group of morphine (Figure 13) with another alkyl group. In the case of Naloxone, the 
methyl group would be replaced with an allyl group. This method is particularly difficult for the 
synthesis of Naloxone however, because this process requires the demethylation of a very stable 
and unreactive quaternary salt (Figure 13). Treatment of quaternary salts with nucleophiles 
results in deallylation instead of demethylation when the original product is a natural opioid such 
as morphine. Other opioid antagonists such as naltrexone and methylnaltrexone do not face this 
issue. To bypass this issue instead of starting with morphine, Naloxone is created beginning with 
a molecule known as oxymorphone (Endoma-Arias, Cox, & Hudlicky, 2013).  
 
 
Figure 16. shows the two most common resonance 
structures of a ketone. One containing a double bonded 
oxygen and the other a single bonded negatively charged 
oxygen. 
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Naloxone semi-synthesis procedures share common features including the protection of 
the reactive ketone group, the use of Burgess reagent, and the Grignard reagent. A protecting 
group disguises a the highly reactive structure, in the case of Naloxone a ketone group, so that a 
reaction can occur in a less reactive area of the molecule. A ketone, is any molecule with a 
double bonded oxygen and a carbon chain or other elements (commonly denoted “R” groups) on 
either side of the double bonded oxygen, as seen in Figure 16.  The central carbon of a ketone is 
especially reactive because of the temporary charge associated with the oxygen. This charge is 
present in only certain forms of molecules, called resonance structures.  A resonance structure is 
a temporary configuration of a molecule, any molecule can have several resonance structures. 
The temporary  charge of the resonance structure makes a ketone susceptible to reactions. The 
goal of using a protecting group is to prevent an unwanted reaction from occurring. Protecting 
the ketone can include transforming the ketone into a ring structure (using cyclic acetals) or the 
attachment of a carbon chain to the ketone. The method used to create Naloxone uses the first 
option and transforms the ketone group so that it becomes part of a ring structure. The goal of 
using a protecting group is to prevent an unwanted reaction from occurring. As seen in Figure 17 
after the reactive group is masked, the desired reaction used to obtain your desired product can 
be performed in the correct location. Without the protecting group the reaction affects the ketone 
as it is a very reactive group, the chemistry would occur at the wrong place and an incorrect 
product would be created. After the reaction is complete (changing “R” to “W” in Figure 17) and 
the correct product has formed the protecting group can be removed by hydration and the ketone 
group will be returned to its original state (Carey & Guiliano, 2017).  
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The Burgess reagent, also known as methyl (triethylammonium sulfonyl) carbamate is a 
common dehydrating reagent. This reagent transforms secondary or tertiary alcohols (an OH 
connected to either two or three other carbon groups) into their respective aldehyde or ketone by 
oxidation, a type of chemical reaction involving the loss of electrons. This reaction takes place 
efficiently and generally with great yields (Sultane & Bielawski, 2017). The burgess was 
discovered by Edward M Burgess who published his findings in 1968 (Atkins & Burgess, 1968).  
The burgess reagent acts as a dehydrating reagent when is transforms secondary and tertiary 
alcohols into the corresponding alkenes using an anti-elimination pathway, one that acts of 
opposite sides of the molecule. Furthermore, it can also transform amides into nitriles and 
hydroxyoxyamides into oxazolines. More recently the burgess reagent has been investigated for 
Figure 17. Protection groups prevent unwanted reaction from occurring by altering a reactive group, 
such as a ketone, so that it reactivity is reduced. Once the ketone is protected the desired reaction can 
occur without a side reaction. Once the reaction is complete and he desired produce is obtained the 
protecting group can be removed, returning the ketone to its original state. 
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the use of alternative reactions and for synthesis. These functions of the burgess reagent can be 
seen in Figure 18. This includes transforming a primary alcohol into the corresponding methyl 
urethane derivative, forming glycosylamines, and cyclic sulfamides. Most notably the burgess 
reagent was discovered to be a source of heteroatoms (non-carbon atoms) including sulfur, 
oxygen, and nitrogen (Nicolaou et al.,  2004). 
 
 
Figure 18. Common uses of the Burgess reagent including the dehydration of alcohols to 
alkenes, dehydration of amides to nitriles and the conversion of alcohols to carbamates 
(Nicolaou et al., 2004). 
 
 
Figure 19. Examples of alkyl halides and 
aryl halides, both can be used to synthesize 
a Grignard reagent. 
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The Grignard reagent also plays an important role in the synthesis of Naloxone, by the 
addition of an alkyl group. The Grignard reagent was discovered by Fancios Auguste Grignard, 
earning him the Nobel Prize in Chemistry in 1912. Fancois was born in Cherbourg, France in 
May of 1871 and later attended the University of Lyons after he fulfilled his military 
Figure 20. General scheme for creation of the Grignard reagent, the mechanism by 
which is it formed and an example Grignard reagent. The reagent is formed through a 
process involving the formation of free radicals, a reactive element with an extra 
electron. All X’s correspond with a halide (ex. Chlorine or Bromine).   
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requirement. At Lyons he worked with Philippe Barber in the 1890s and submitted his thesis on 
the use of magnesium, and essential part of the Grignard regent, in organic chemistry in 1901. 
This work earned him his doctorate degree in science. His thesis work lead to the discovers of 
the Grignard reagent which he used to create ketones, ketoesters, complex alcohols, nitriles and 
terpene compounds. He was eventually named the dean of sciences in 1929 (The Nobel Prize in 
Chemistry - 1912.). The Grignard reagent is formed by reacting an alkyl or aryl halide (Figure 
19) with elemental magnesium, giving RMgX as the final product. Where R is the alkyl or aryl 
group, Mg represent Magnesium and X the halide (Br, F, or Cl for example). The reagent is 
formed via a free radical intermediate and uses bromine most commonly. A free radical is any 
molecule that has only one electron not bound to anther atom as compared to the common 
unbound pair of electrons. It is important to note that free radicals remain neutral in charge 
despite the unbalance in number of electrons (which carry a negative charge). Furthermore, it is 
the single unbound electron that drives free radical reactions. In the case of the Grignard reagent 
the Magnesium undergoes oxidative addition between the C-X bond. This causes the carbon to 
become neutrophilic and ready for a reaction. This mechanism is illustrated in Figure 20. The 
Grignard reagent is especially useful to chemists because of its adaptability for synthesis and the 
ease at which the compound is created (Orchin, 1989).  Just a few of the many compounds that 
can synthesized using a Grignard reagent are shown below in Figure 2, as well as the use of 
Grignard’s reagent to synthesize Naproxen, a common over the counter painkiller.  The 
properties of these reagents make it optimal for the synthesis of Naloxone.     
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Figure 21. Common compounds that are synthesized using Grignard reagents, they include 
alcohols, ketones, and thiols. The Grignard reagent is also used to synthesize Naproxen the 
painkiller found in Aleve® (Grignard reaction. 2018). 
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As previously discussed, oxymorphone (Figure 22) is successfully used at the as the 
initial molecule which will be transformed into Naloxone and similar drugs (ex. Naltrexone). 
The process begins with demethylation, then ring protection and lastly addition to the previously 
demethylated nitrogen and uses the three essential tools previously described (Protecting groups, 
the Burgess reagent and a Grignard reagent). The synthesis begins with the demethylation of 
oxymorphone via the burgess reagent and the iminium ion forms oxazolidine. The scheme for 
this reaction is found in Figure 23. The C-6 ketone is protected under mild conditions yields an 
acetal (molecule 12) in 82% yield (Figure 24). This process prevents any reaction with the much 
more reactive ketone on carbon 6, 
thus allowing the less reactive 
functional groups to be targeted 
and manipulated. After the 
protection process occurs the result 
is treated with the Grignard 
reagent, which in this case is 
derived from allyl bromide, 
cyclopropyl methyl bromide, or 
cyclobutylmethyl chloride 
depending on the desired product (Naltrexone, Naloxone, etc.). Treatment with the Grignard 
reagent results in N-alkylated products (structures 13a, 13b, or 13c in Figure 24), the variation of 
the alkyl group is determined by the specific reagent used. To synthesize Naloxone, the protected 
oxazolidine is reacted with allyl bromide as to add the essential vinyl group to the compound 
(13a). The protected group is then removed by hydrolysis and the final product is formed. This 
Figure 22: Oxymorphone’s structure (Endoma-Arias et 
al., 2013) 
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process is used with high yield rates to produce naloxone as well as naltrexone and nalbuphine 
when different Grignard reagents are used  (Endoma-Arias et al., 2013).   
 
 
 
 
Figure 23: Synthesis of oxazolidine form oxymorphone (Endoma-Arias et al., 2013). 
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 Typically, the N-methyl group of a molecule, an opioid in this case, is replaced using one 
of two methods. Either the selective N-demethylation of salts or palladium-catalyzed N-
demethylation. Neither of these processes work well for synthesize Naloxone however, scientists 
had to modify these methods for better yields. While these methods worked for simple alkyl 
groups, such as those necessary to make Naltrexone (a cousin to Naloxone), the structure of 
Naloxone prevents it from being compatible with these methods. The nucleophilic demethylation 
involved in the first method interacted with the allyl group, preventing the synthesis of 
Naloxone. Using a palladium catalyst produced a complex mixture of products, giving a useless 
Figure 24: Scheme 1 synthesis of Naloxone Naltrexone, and Nalbuphine through the utilization 
of the burgess reagent, protection, and Grignard reagent (Endoma-Arias et al., 2013). 
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chemical modge podge mixture of molecules. The method described previously using the 
Grignard reagent to open the oxazolidines after protection of the ketone group was found to be 
the most successful and useful method. Furthermore, the oxazolidines created using the Burgess 
reagent can not only be used to make Naloxone, but also Naltrexone, and Nalbuphine by 
treatment with different Grignard reagents. For these reasons the method described is the 
superior route to synthesize Naloxone (Hudlicky, 2015).  
 
-Biochemical Mechanism- 
 
 Opioids work on a molecular level that combine to have effects on the structures of the 
brain and other regions of the body. One study looked at the effects of the opioid morphine on 
different parts of the brain when the drug is being administered for non-pain-relieving purposes 
(when the medication is being used recreationally). They found one region that is greatly 
affected by the presence of opioids, the limbic is the system. The limbic system is responsible for  
sensations of pleasure and relaxation and responds to the opioids naturally produced by the body 
as well as synthetic opioids which mimic the effects of naturally occurring opioids. They found 
that morphine activated the lateral pain pathway, which includes the somatosensory cortex and 
the ventral posterolateral thalamus. Morphine also activates and inhibits the medial pain 
pathway, which contains the anterior cingulate cortex and medial dorsal thalamus. Both of these 
pathways are regions of the brain that are activated in response to pain and pleasure. What does 
this mean in terms of opioids? Overall the researchers found that morphine activated the sensory 
parts of the brain and did not suppress the brains total activity as was previously thought (Su et 
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al., 2012). On a molecular level, natural and synthetic opioids work the same way in the brain. 
Opioids bind to an opioid receptor and cause the associated euphoric sensations. There are 
currently four receptors and corresponding genes that have been identified at a cellular, 
molecular, and pharmacological level these are: The Mu (µ) receptor, the delta (δ) receptors, 
Kappa (κ) receptors, and opioid receptor like- 1 (ORL1). Of these receptors the µ receptor is 
most commonly targeted for analgesia, and is also a route to the dopamine reward center in the 
brain making it susceptible for the formation of addictions (Al-Hasani & Bruchas, 2011). The µ 
receptors are those that a affected by opioids such as hydrocodone and codeine.  
 Unlike originally speculated, opioids have different cellular effects on the brain than 
endogenous opioid created by the body, such as endorphins, the chemical responsible for the 
natural high associated with intense workouts. These differences in the cellular effects on the 
neurons can explain the why opioids, such as oxycodone and fentanyl produce such addictive 
highs. Using a “sensor” molecule that binds to the µ receptors along with the opioids, scientists 
at the University of California San Francisco, were able to take a closer look at the interactions 
between these receptors and the opioids (Stoeber et al., 2018). This research greatly increased 
understanding of what is happening at these receptors. What was previously thought, was that 
after binding to the receptor both the opioid and the receptor would be taken into the neuron by 
an endosome, using a method of bulk transport where an infoldings of the cell membrane forms 
and eventually enters the cell. The team of researchers found that once in the cell the µ receptors 
remain active, overturning the previous idea that they became inactive once inside. Furthermore, 
the research team found that these transport bubbles traveled to the Golgi apparatus, an organelle 
within the cell, were they had further cellular action. The scientists found that opioids, such as 
morphine, can travel directly to the Golgi apparatus as well, without the assistance of transport 
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proteins or other receptors. Endogenous opioids did not have any effect once they reached the 
Golgi apparatus and took about three times as long to reach this structure. This time difference 
can play a large role in the addictive characteristics of opioids, as pain killers like morphine and 
hydrocodone that act faster typically have more addictive effects (Smith, 2018).  It is still not 
entirely clear what this means but it a finding a significant difference between endogenous and 
synthetic opioids that is crucial step in understanding addiction.  
 
Figure 25. Dopamine’s structure (Anderson, 2011).  
 
 When observing  the effects opioids scientists have found that there was an increase in 
the neurotransmitter dopamine within the brain. Dopamine is mainly responsible for motivation 
and is essential to the reward-motivated behavior. Dopamine’s structure is illustrated in Figure 
25. Opioids cause dopamine to be released in the ventral tegmental area (VTA) a region of the 
brain (seen in Figure 26) that is strongly associated with addictive behaviors. It was discovered 
in 1992 that the levels of dopamine were indirectly controlled by opioids. This means that an 
opioid deactivates neurons that produce chemicals that prevent the release of dopamine, these are 
known as inhibitory neurons. Because these neurons are not functioning, the levels of dopamine 
will rise in the brain. These inhibitory neurons are prevented form functioning by 
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hyperpolarizing a cell, increasing the positive charge in the cell so drastically that an action 
potential, the electrical signals of the brain, cannot fire (Johnson & North, 1992). Later in 2014, 
using this foundational research another team of scientists at the University of California- San 
Francisco proposed an alternative method. Their research revealed that not only did opioids 
cause in the indirect increase in dopamine by preventing the inhibitory neurons from preventing 
the release of dopamine but also through the direct action of neurons. In other words, they found 
that neurons also released dopamine in response to the presence of opioids. They proposed that 
there are multiple factors that are controlling the levels of dopamine in the brain (Margolis et al., 
2014).  
 
Figure 26. The ventral tegmental area (VTA) can been seen as the red dot on both the horizontal 
and vertical images of a brain (MacPherson, 2008).  
 
Decreased or secession of breathing is the most dangerous part of an opioid overdose. A 
lack of oxygen is the ultimate cause of death in an overdose as the individual eventually stops 
44 
 
 
breathing. Even when death does not occur individuals who suffer from an overdose may have 
suffered from anoxic brain damage as a result of prolonged reduction in the amount of oxygen 
availiable to the brain.  Opioids interfere with the part of the brain that regulates breathing, this 
system recognizes the concentration of carbon dioxide, a molecule that is exhaled, in the brain to 
determine when a breath is needed. When the levels of carbon dioxide in the brain increase, 
respiration rate increases to remove the CO2 from the blood and replace it with oxygen. When 
the levels of CO2 become too low, respiratory rates decreases which allow the balance between 
carbon dioxide and oxygen to be restored. During an overdose this system is not functioning 
properly. Even though the levels of carbon dioxide are increasing in the brain respiratory rate 
does not increase to compensate for the imbalance. Thus, even though the person is beginning to 
suffocate, their body is unable to correct the issue through normal regulatory mechanisms (White 
& Irvine, 1999). Administering Naloxone in a timely manner can prevent both death and anoxic 
brain damage.  
 We know how opioids affect the brain at a molecular and structural level and how 
opioids affect respiration but how does Naloxone counter act opioids? The general mechanism 
by which Naloxone works in the brain is a simple one, by acting as an antagonist, it binds to a 
receptor and prevents the action of the opioid on the neurons (Figure 27). Initially, the majority 
of the µ receptors are overwhelmed by the opioids, whether it be heroin or prescription opioids. 
As the amount of Naloxone increase is the brain the Naloxone begins to replace the opioids on 
the receptor, because of their higher affinity Naloxone has for the receptor relative to the affinity 
of the opioid (Steps 2 and 3). The affinity is based on the chemical structure and how molecules 
pair with the receptor. Stronger interactions between the receptor and the molecule translate into 
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a higher affinity. The receptor prefers to bind to Naloxone over and opioid, allowing Naloxone to 
kick out the drug and halt the overdose (Rzasa Lynn & Galinkin, 2018). 
 
 
 
 
 
Naloxone must also be able to cross the blood brain barrier to reach the cells effected by 
the opioid. This feat is easily achieved because Naloxone is very similar in structure to opioids 
found naturally in the brain. The blood brain barrier is not a wall or fence as it described by its 
name, but it is a collection of cells found on the capillaries of the brain that control what is 
Figure 27. The mechanism action of Naloxone in the brain is built around the affinity of the 
drug. Initially, opioids are bound to µ receptors on neurons (1). As the concentration of 
naloxone increases Naloxone replaces the opioid on the receptor (2) and the opioid is 
released (3). In the end, the opioids are bound to µ receptors, preventing the action of the 
opioid.  
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entering and exiting the blood of the brain, as seen in Figure 28. The blood brain barrier is a gate 
keeper that control what molecules can pass and enter the brain. It also maintains the 
microenvironment of the brain so that it is conducive to its function and prevents molecules that 
will disrupt normal neurological function form entering the brain. The two main components of 
the blood brain barrier are the endothelial tissue that make up the capillaries and astrocytes, a 
type of glial or neurological support cell. Astrocytes are responsible for regulating the 
permeability of the endothelial cells through tight junctions. Tight junctions are structures made 
up of cadherin proteins that act as glue between cells. The extremely strong tight junctions of the 
blood brain barrier practically eliminate the paracellular pathway, a route molecule can use to 
travel between cells without passing through them. Essentially the sneaky way around the cell. 
This prevents molecules from sneaking into the brain and forces them to travel through the cell 
and be subject to the “gatekeeper” function of the endothelial cells. There are also transport 
proteins imbedded in the membrane of the endothelial cells, transport proteins allow for the 
movement of specific molecules and prevent the passage of others. While small and hydrophobic 
 
 
Figure 28. Microvasculature on the 
brain regulate the molecules that 
enter and exit the brain. The two 
main components of the blood 
brain are the endothelial cells that 
compose the capillaries and the 
astrocytes that regulate the 
endothelial cells and thus the blood 
brain barrier (Abbott, 2002). 
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molecules can pass through the blood brain barrier without a transporter protein other larger and 
hydrophilic molecule require one. An important example of this is glucose, which require the 
GLUT 1 transport protein to enter the brain. It is essential for glucose to enter the brain as it is 
the brains preferred energy source. There are also instances of receptor mediated endocytosis 
where a large number of molecules are taken into the cell after one bind to a receptor. This 
method uses a technique where the cell membrane folds in on itself creating a transport vesicle 
containing the molecule on the inside of the cell (Abbott, 2002). This is a very similar method 
that is was previously discussed for the intake of opioids into neurons.  It is essential that 
Naloxone cross the blood brain barrier and enter the central nervous system where the opioid 
overdose is taking place.   
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Opioids enter the brain through a p-glycoprotein transport protein, this protein recognizes 
the structure of opioids and allows them to pass through the blood brain barrier and enter the 
central nervous system, this is diagramed in Figure 29. There is some debate regarding the 
mechanism by which Naloxone enters the brain. Naloxone can enter by passively diffusing 
through the membrane, but it can also hitch a ride on a transport protein. The question of what 
transport protein that is under scientific inspection. It is suspected that Naloxone and other 
similar opioid antagonists enter the brain using the same or a similar p-glycoprotein that opioids 
use (Schaefer, Tome, & Davis, 2017). However another study found that because Naloxone was 
still able to enter the brain after the p-glycoprotein transporter were disabled that this protein 
does not play as crucial of a role in the transport of Naloxone across the blood brain barrier 
(Suzuki et al., 2010). While the mechanism is not entirely understood there is no doubt that 
Naloxone can cross that blood brain barrier and does so effectively. Interestingly enough, 
Naloxone enters the brain and acts similarly to the potent and dangerous synthetic opioid 
fentanyl. Both molecules can cross the bool brain barrier by simple diffusion, but they also use 
transport channel proteins. Both have a blood effect- site equilibration half- life of 6.5, which 
indicates the ease at which a molecule transfers between the plasma of the blood and the brain 
(Rzasa, Lynn, & Galinkin, 2018). 
One of the pitfalls of Naloxone, is that patients who are administered doses of Naloxone 
they can go through an “overdose aftershock”.  An “aftershock” overdose is one that occurs after 
some time after Naloxone is administered. After a dose of Naloxone is given, the highest 
concentration is at about five minutes after administration. This concentration slowly decreases 
over time and much faster compared to molecules such as morphine whose concentrations 
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decline over a much longer period, hours instead of minutes. The fact that Naloxone dissociates 
with opioid receptors almost as fast as it associates with them (allowing an opioid molecule to 
regain its place) combines with the declining concentration to create a potential problem of an 
“after shock” overdose. Because of the risk of “aftershock” overdoses it is vital that individuals 
remain under surveillance after receiving Naloxone. Many times, people refuse medical care 
following a Naloxone rescue thinking that they are safe when they are at risk for a subsequent 
overdose. EMTs and paramedics encourage patients to go to the hospital to be sure they do not 
suffer another overdose, but it is within the rights of the individual to refuse this care (Rzasa 
Lynn & Galinkin, 2018). 
 Many opioids can outlast Naloxone giving the opioid an opportunity to strike again once 
the Naloxone molecules have left the individual’s brain. This phenomenon is dependent on the 
characteristics of the opioid involved, such as the time to remove the opioid form an individual’s 
system and the degree of affinity toward the opioid receptor in the brain. Just like Naloxone 
these qualities are dependent on the chemical structure of the opioid. Those that remain in the 
brain longer pose a greater danger of an “aftershock” overdose and the effectiveness of the 
Naloxone treatment can decrease. For instance, a dose of 13µg/kg of Naloxone will be enough to 
occupy half of the µ opioid receptors in the brain. However, this may not be a high enough 
percentage when dealing with an extremely high concentration of opioids or a very potent 
opioid, such a fentanyl.  Furthermore, long lasting and extended release drugs such as extended 
release oxycodone or hydrocodone can out last the effects of Naloxone. One example of how 
different pain killers are affected by Naloxone include morphine and one of its metabolites. 
Naloxone requires more time to antagonize a metabolite of morphine, morphine-6- glucuronide 
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(M6G) than morphine because of the minute differences in molecular characteristics (Rzasa 
Lynn & Galinkin, 2018).  
For most opioid overdoses the ability of Naloxone to increase respiratory rates depends 
on the interactions of the opioid and the receptor. These factors cannot be influenced by the 
concentration of Naloxone in the brain and are not made more effective by increasing the dose. 
However, in cases such as fentanyl, which have a very short interaction and a higher affinity 
towards the receptors can be affected by the dose of Naloxone given. A higher dose of Naloxone 
can make it easier for the individual molecules of Naloxone to bind to the receptor by 
outcompeting the fentanyl molecules by sheer number but is not a guarantee of an effective 
overdose reversal. This pitfall of Naloxone means that to “customize” the dosage to the specific 
opioid present, especially when it is unknown what drug the individual is overdosing on, a 
patient may need multiple doses of Naloxone. However, this is a small problem compared to the 
overall effectiveness and versatility of the drug (Rzasa, Lynn, & Galinkin, 2018).  
 
Figure 30. Narcan ® nasal spray and the Evzio ® autoinjector are two methods used for fast 
administration of opioid antagonists (Basler, ). 
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Naloxone can be administered through several routes and is safe enough to administer 
multiple doses of the drug in a short period of time. The mechanism by which Naloxone reverses 
overdoses and the fact that Naloxone its self does not have any have and detrimental or malicious 
effects on the body means that it is safe to administer several doses of the drug or even to an 
individual who has no opioids in their system. It is even encouraged that if individuals do not 
improve after a few minutes to administer a second dose, with the idea that the drug can override 
the opioid more successfully when in higher concentration in the brain. Furthermore, the 
increasing routes to administer the drug paly a large role in the versatility of the drug in both in 
institutions and in the field. Naloxone can be administered intravenously, with a subcutaneous 
injection, and through a nasal spray, Figure 30. Recent developments have led to products such 
as Evzio ®, an automatic intramuscular injector as well as the nasal spray Narcan ®. There has 
also been the use of an adaptor tool that can be used to convert a syringe into a device capable of 
administering a nasal spray, allowing generic Naloxone to transform into a tool equivalent to 
Narcan ® (Weaver et al., 2018).  
Many studies have been done that have verified the effectiveness of these devices. The 
advantages of the intranasal administration and intramuscular administration are large in the 
hands of first responders in the field. The most evident advantage being the time saved by not 
needing to start and receive an IV infusion. The few more minutes that are spared are the 
boundary between life and death. Both the intranasal and intramuscular administration routes had 
similar success rates when in the hands of first responders, but the intranasal devices offer an 
advantage to lay persons. For this reason, programs providing lay people with Naloxone have 
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begun to appear across the country. The side effects of Naloxone administration have often been 
compared to the effects of detoxing from an opioid. These include agitation, nausea, vomiting, 
tremors, and excess sweating. These symptoms are, interestingly enough, reduced when 
intranasal is used over intramuscular administration, yet another advantage for intranasal 
administration (Weaver et al., 2018).  The chemical nature, simple synthesis methods, safety and 
various routes of administration make Naloxone an advantageous drug to combat the opioid 
epidemic. 
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Utilization and Accessibility of Naloxone 
  
Naloxone is a miracle drug capable of rescuing people from a certain death but no good can be 
done if the drug is not in the right hands. Naloxone has been used for decades but only recently 
has been made more availiable to the public. However, there are still barriers that prevent 
Naloxone from reaching the battle grounds of the opioid epidemic. The largest barrier that is 
preventing the most appropriate utilization of Naloxone is rooted in Naloxone’s status as a 
prescription drug. Naloxone is considered a prescription medication in most states, and just like 
any other prescription Naloxone requires the action of a physicians or other providers to be 
distributed, whether they are opioid users or family members of opioid users. Even though state 
legislation is increasing access of Naloxone across the county they all must work around the fact 
that Naloxone is prescription drug. This status poses direct limitations on the accessibility of 
Naloxone. Physicians may not be willing to prescribe Naloxone or ,as in many cases, are limited 
by the number of prescriptions they can write for Naloxone each year. Access to a physician can 
limit and individual and a community to access to Naloxone, to that communities lacking 
physicians have reduces access to Naloxone. Furthermore, drug treatment facilities, where 
Naloxone is more readily accessible, are few and far between (Kim, Irwin, & Khoshnood, 2009).  
Despite the new legislation regarding Naloxone and Good Samaritan Laws, protecting 
individuals who proscribe and administer Naloxone, many prescribers are still wary about 
prescribing Naloxone due to legal prosecution. Many of these legal concerns are largely 
theoretical and have not occurred before but many physicians are not willing to risk their career 
and the potential lives that they would have otherwise. Good Samaritan laws are allowing for lay 
people to administer Naloxone but not without potential consequences. For example, in 
Maryland and Wyoming, assisting an unlicensed practice of medicine warrants criminal 
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prosecution of both the individual and the prescriber. In the case, a lay person administering 
Naloxone is an unlicensed practitioner of medicine and the physician prescribing the Naloxone is 
assisting this individual (Brodrick et al., 2105). As you can see in Figure 31, even though there 
are laws increasing the access of Naloxone in every state there continue to be consequences 
associated with prescribing Naloxone. Physicians can be prosecuted in stats such as Iowa, 
Oregon, and Tennessee. Furthermore, Figure 32 displays the regulations regarding lay people 
and third-party prescribing. Most states have criminal prosecution when a person who does not 
have prescription possess Naloxone while the majority of states give immunity to lay people that 
administer Naloxone. When health care professionals do provide Naloxone, it is important that 
physicians are confident in the individual’s ability of administer Naloxone and provide sufficient 
education. Education for identification of an overdose includes teaching people to look for 
lessened or non-existent breathing and the signs that follow, such as cyanosis of the finger tips 
and lips. The education must also include instruction on how to administer Naloxone, especially 
when an atomizer is used to convert an intramuscular dose of Naloxone into a nasal spray 
(Brodrick et al., 2105). Proper patient and family education may help in the effort to protect 
physicians form prosecution. 
Converting the status, of  Naloxone to an over the counter medication offers a solution to 
this issue. The danger of changing Naloxone’s status to over the counter is minimal as the 
medicine does not cause any harm, even when opioids are absent. The most likely concern may 
be that individuals are more likely to use more of an opioid or begin using an opioid knowing 
that they can use Naloxone as a safety net. Many people have brought up this issue in regard to 
general Naloxone use as a prescription too.  However, the potential for increased opioid is not 
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worth the countless lives that can be saved by taking this huge step to make Naloxone over the 
counter, especially in a country where naloxone use is already skyrocketing.  
 
 
Figure 31. Laws regarding Naloxone access in the United States considering the liability of prescribers 
their criminal, civil and professional liability. Where blue is yes and yellow is no (Naloxone overdose 
prevention laws.2017). 
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The opioid epidemic is issue for which we have solutions, increasing the access of both 
emergent and long-term addiction treatments while reducing the prescribing of opioids, ideally 
with a superior alternative for pain management. Regarding Naloxone, increasing accessibility of 
the medicine includes sharing the life-saving drug with the public but also ensuring that it is 
availiable where and when it is needed. For this reason, it is essential that first responders are 
armed with Naloxone. Paramedics have been carrying and administering Naloxone for many 
years and have greatly contributed to the efforts to weaken the grasp of the opioid epidemic. 
However, they are often times not the first emergency personnel to arrive on the scene of an 
Figure 31. Laws regarding Naloxone access in the United States considering the liability of 
prescribers their criminal, civil and professional liability. Where blue is yes and yellow is no 
(Naloxone overdose prevention laws.2017). 
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opioid overdose, constraining the effectiveness of Naloxone due to the time dely. More time than 
not Emergency Medical Technicians (EMTs) and Law Enforcement Officers (LEOs) are the first 
individuals to arrive on scene. Equipping these individuals with Naloxone is key to reducing the 
effects of the opioid epidemic for two reasons (Davis et al., 2015). The first being the time 
sensitivity of the drug, the longer an individual is experiencing the respiratory depression that 
goes hand in hand with an overdose the more likely that they will suffer from anoxic brain 
damage. This damage to the brain cannot be reversed even if the overdose is. The second reason 
why it is essential and has been successful in reducing the number of opioid related deaths is that 
the vast majority of first responders in rural areas are EMTs and LEOs. Overdosing in a rural 
area puts an individual at a much higher risk to death by overdose because it takes more time for 
emergency responders to arrive on scene, most often due to the combination of longer travel time 
and a shortage of medical professionals and emergency services as there are substantially fewer 
Figure 32. Opioid overdose death rates and odds of Naloxone use in urban, suburban, and rural 
areas. The odd of receiving Naloxone in a rural area decreases while the rate of opioid overdose 
increases (Faul et al., 2015).  
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paramedics working in rural areas. The odds of receiving a dose of Naloxone drops drastically in 
rural areas while the rate of opioid related deaths increases (Figure 32). By giving law 
enforcement and EMTs direct ability and access to Naloxone, lives will be saved in rural areas. 
Simply because we will be one step closer to placing Naloxone in the right hands and at the right 
time (Faul et al., 2015).   
 
 
 
 
 
  
 
Figure 33. Laws under which Law Enforcement Agencies can carry Naloxone. Only Medical 
Orders and Explicit Authorizing Statues are directly addressing LEO’s ability to administer 
Naloxone. General Naloxone Statues apply to all citizens of a state (Davis et al., 2015). 
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Across the country more laws are directly addressing the ability of law enforcement and 
EMT to carry and administer Naloxone. However, only thirteen states have law that directly 
address the ability to carry Naloxone and the supply of Naloxone to law enforcement and EMTs. 
Officers in other states carry and administer Naloxone under the laws the pertain to all of the 
citizens and many purchases their own doses of the lifesaving drug. Every state has at least one 
immunity law that protect good Samaritans form legal prosecutions who provide assistance in an 
emergency (Davis et al., 2015). These laws include the administration of Naloxone when the 
individual is informed about the medicine, how to recognize drug overdoses, and how to 
administer Naloxone. Individuals must be acting in “good faith”, they must have the intention to 
do good and prevent harm. Therefore, an individual who is not knowledgeable of Naloxone or its 
administration protocol does not necessarily meet this requirement as they are not sure if their 
actions will be helpful or exert more harm (Green & Doe- Simkens, 2016). This issue is 
addressed by the education individuals, citizens, law enforcement, and emergency medical 
technicians alike, receive with their doses of Naloxone. Pharmacists and providers are required 
to share this information with individuals with Naloxone prescriptions or those acting under state 
wide laws (Davis et al., 2015).  
Given the severity of the opioid epidemic and the initiatives to broaden the 
recommendations for Naloxone’s use, we would expect to see an exponential increase in the 
utilization of the drug. However, between the years 2009 and 2015 the number of naloxone 
prescriptions only increased by 400,000. Furthermore, retail prescriptions remained the same 
while the percentage of growth attributed to EMS providers and clinics increased from 14% to 
29%. The cost of Naloxone is at part to blame for this trend. Like many other medications the 
price of Naloxone has been rising in recent years. Currently there are two doses of Naloxone 
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availiable a 0.4 mg/mL dose and a 1 mg/mL dose. There are generic versions of the drug but the 
newer intranasal and intramuscular autoinjector doses of Naloxone are not availiable as a generic 
drug. This is a large obstacle in the efforts to combat the opioid overdose because these methods 
administration are the best option for a lay person to administer Naloxone. One manufacturer, 
Adapt, produces Narcan ®, the intranasal formula, and another produces Evzio ®, the 
intramuscular autoinjector. Thus, these companies can drastically increase the price of their 
product without the regulatory nature of generic options and market competition. As you can see 
in Figure 34 over the span of two years the price of Evzio ® has increased by more than 500%, 
to $4,500 for two autoinjectors. Even the generic brands of Naloxone have seen a price increase, 
Hospira’s product has increased in price by 129% over four years. Even though there are three 
companies producing generic Naloxone, the largest manufacturer is Hospira. The two smaller 
companies, Mylan and West-Ward, cannot compete with Hospira despite the lower price they 
offer. Furthermore, only one company, Aphistar, produces a 1 mg/mL dose that can be used off-
label as nasal spray, with the use of an atomizer attachment. We see a similar pattern of a 95% 
increase in the price of this company’s product as well. While the name brand Naloxone products 
are exponentially increasing in price the generic options are getting more expensive as well 
(Gupta, Shah, & Ross, 2016).  
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There are several ways in which the increasing price of Naloxone can be addressed. To 
begin with manufacturers must be held responsible for the price jump and requests for a price 
reduction and increased transparency should be demanded of the companies (Gupta et al., 2016). 
U. S. senators Susan Collins (R- ME) and Claire McCaskill (D-MO) have written letters asking 
Naloxone manufacturers to explain their price increases (Tirrell & Mangan, 2016). A similar 
response occurred when prices were rising exponentially on another life saving device, the 
EpiPen causing increase in media coverage of the outlandish prices. The government can also act 
and purchase Naloxone in bulk, creating a stable demand for the drug. Giving more companies a 
reason to begin producing Naloxone and more competition for the lower bidder. The purchased 
Naloxone can then be given to states based on their need. This strategy was effectively used for 
the manufacturing of vaccines. The government could also invoke federal law 23 U.S.C section 
1498, which would allow them to draw a contract with a manufacturer to produce less costly 
alternatives in exchange for royalties from the government. This strategy was used to obtain 
ciprofloxacin during the anthrax threat of 2001. There have also been proposals to allow the 
Figure 34. Price comparison of Naloxone manufactured by various pharmaceutical companies 
(Gupta et al., 2016). 
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importation of generic form international manufacturers with approval from an agency 
comparable to the Food and Drug Administration (Gupta et al., 2016). Regardless of the action 
that is taken, something must be done to decrease the price of Naloxone and thus expand its 
capabilities to combat opioid related deaths.  
 Despite the rising prices, Naloxone continues to be a cost-effective method to save lives. 
One study used a cost-effectiveness analysis program to compare scenarios where Naloxone had 
been distributed among heroin users and when it had not been distributed. The researchers used 
national data for estimates of the overdose, overdose mortality, naloxone effectiveness, and rates 
of drug cessation from epidemiologic studies. The study measured costs, quality- adjusted life-
years (QALYs), and incremental costs per QUALY gained. They compared this data to the 
standard $50,000 or less per QALY gained as the standard definition of cost- effectiveness. 
Considerations were also made as to the number of overdoses that are reversed by emergency 
medicine providers such as paramedics. These researchers found that the incremental cost-
effectiveness ratio was much less than the $50,000 bench mark at $421 in the base case or 
$2,428 when considering the cost other health care expenses that people who are addicted to 
heroin are likely require. Furthermore, they found that Naloxone became even more cost 
effective as in scenarios when the treatment was availiable to more people, including lay-people. 
The only scenarios in Naloxone was not cost effective were when a distribution which typically 
costs $25 with contractual agreements between the suppliers and programs exceeds $4,480, if the 
average emergency care cost for any event, from stiches to a heart attack, exceeds $1.1 million, 
or if the survival rate from an overdose after Naloxone administration is reduced to 0.05%. These 
extreme scenarios are very unlikely to occur and thus Naloxone will continue to be a life-saving 
and cost effective drug for years to come (Coffin & Sullivan, 2013). 
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 Expanding the availability of Naloxone to the layperson has been instrumental in 
progress towards expanding the use and lifesaving potential of Naloxone. Communities with 
programs to distribute Naloxone saw a 27-46% in the mortality rates associated with opioid 
overdose. Of the individuals who acted and administered a lifesaving dose of Naloxone, 90% 
were drug users who have much more exposure to overdoses. There are several factors that have 
brought Naloxone into the hands of the public: third-party prescriptions, Naloxone take home 
kits, and the efforts of pharmacists (Green & Doe- Simkens, 2016). Currently the number and 
type of people who can carry and administer Naloxone is on the rise. Health care professionals in 
38 states can now prescribe Naloxone to not only individuals who are at a higher risk of an 
overdose, but to their family members as well. This third-party prescription idea was adopted 
form the Expedited Partner Therapy initiative, in which individuals who tested positive for STDs 
were given prescription medication for themselves and their partner with the intention of treating 
all parties involved. A third-party prescription acknowledges that the individual in danger of 
overdosing may not seek help from a medical professional and that if they do overdose they will 
not be able to administer Naloxone to themselves. While some states include friends and 
caregivers in their definition of a third-party others only include immediate family members. The 
lay-person’s access to Naloxone has also increased by the use of standing orders. In this case a 
prescriber issues a prescription for any individual who meets a requirement, set by the prescriber. 
This allows individuals to go directly to a pharmacist and obtain Naloxone after demonstrating 
how they meet the requirement.  The requirement can pertain to an individual with an opioid 
addiction or to their friends and family (Davis & Carr, 2015).  
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Take home Naloxone kits provide an easy to use form on Naloxone, instruction on 
administration, information on identifying an overdose, as well as a mask to deliver rescue 
breaths through. Typically Naloxone take home kits are distributed by community lead 
organizations and target people within the community that are using opioids, as these people 
witness more overdoses than any other group of people (Lewis et al., 2016). The introduction of 
easily administered lead to a much greater access of Naloxone to the lay person and the tools 
required of a take home kit. Various delivery methods were evaluated in the process of choosing 
the most effective and easily administered delivery system. Inhalation of the drug was excluded 
from the possibilities as individuals who are overdosing have decreased respiration rates or have 
stopped breathing all together. Both sublingual and buccal routes were not suited for the 
emergency and could easily be affected if the individual overdosing has increased secretions in 
their mouth or if they vomit while overdosing. The best route for Naloxone delivery by a lay 
person was determined to be intranasally. This method is simple to teach to people and is very 
Figure 35. Selection of potential Naloxone administration routes and inclusion criteria. 
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effective at stopping the overdose. Figure 35 displays the administration routes evaluated and the 
criteria they were to meet (Strang et al., 2016). Intranasal as well as intramuscular naloxone is 
provided in kits in communities across the country.  
 
 
 
Community based opioid overdose prevention and response (OOPR) programs began to 
arise in the U.S. in the late 1990s. The first program was in Chicago, but more have been created. 
Sense the creation of Chicago’s program OOPR has expanded to 136 program that manage a 
combined 644 Naloxone distribution sites across the country. However, in 2013 there were 
twenty states who lacked a OOPR program and nine states has less than one person per 100,000 
equipped with a Naloxone rescue kit (Green & Doe- Simkens, 2016).  One example of a 
community-based distribution of Naloxone is the Baltimore Student Harm Reduction Coalition 
(BSHRC). The program uses the third-party prescription law in Maryland to give Naloxone to 
both users and people likely to witness an overdose. It is the state’s first community-based state-
Figure 36. Survey responses of individuals completing BSHRC’s Naloxone training program. 
Pre and Post-test results show an increased confidence in ability to administer Naloxone and to 
discuss the dangers of overdose with family and friends at risk of an overdose (Lewis et al., 
2016).  
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authorized organization for Naloxone training and distribution. Individuals who take part in the 
program receive training to administer intramuscular naloxone, a free take home Naloxone kit 
with two doses of Naloxone, and a prescription for Naloxone from a volunteer medical provider. 
BSHRC obtains the naloxone through contractual agreements at a cost of $15.84, with the cost of 
a part- time staff member the total cost of each Naloxone kit totals to $20.01. Evaluation of the 
program saw that individuals were more confident in their ability to deliver Naloxone and 
believed that it is essential to discuss the risk of overdosing with their loved ones (Figure 36). In 
just eight months the program was able to distribute Naloxone to 285 participants and received 
reports of three successful overdose reversals (more reversals that were not reported may have 
occurred as well). The outstanding record and effectiveness of BSHRC’s training program 
should serve as a model for programs across the country (Lewis et al., 2016) 
 The battle against the opioid epidemic does not solely lie in the hand of physicians and 
other professionals with the ability of prescribe medications. The addition of pharmacists to the 
playing field offers several advantages for the effort to expand access of Naloxone. Pharmacists 
are knowledgeable and well-trained professionals capable to distributing Naloxone and educating 
individuals about its administration. Furthermore, often times a pharmacist is a most accessible 
health care professional, especially to individuals who cannot afford the doctor’s visit to obtain a 
prescription for Naloxone (Davis & Carr, 2015). The National Association of Boards of 
Pharmacy have voiced their support for the utilization of pharmacists noting that it “recognizes 
the value of pharmacists in assuring optimal medication therapy and promotes the pharmacist’s 
role in delivering opioid overdose reversal therapy” (NABP issues policy statement. 2014). 
Currently there are several ways in which pharmacists are providing Naloxone. Figure 37 
displays the laws by state that and the role pharmacists play. In some states the use of standing 
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order allows a pharmacist to dispense Naloxone to any person that meet the criteria of the 
standing order, typically these states have a state-wide standing order issued. Some states allow 
pharmacists to prescribe Naloxone on their own authority, just as a physician is able to, allowing 
them to bypass the previously necessary authority of another medical professional. These states 
include the following four states: Idaho, Connecticut, North Dakota and New Mexico. Some 
pharmacist working for government agencies, such as Indian Health Services, have this authority 
as well. In the cases when pharmacists are allowed to prescribe Naloxone, they have the same 
requirements as  prescribers. Lastly, several states allow pharmacists to dispense Naloxone under 
a statewide protocol issued by a professional board or they can enter into an agreement with a 
physician or physician group where the pharmacists can dispense Naloxone to individuals to 
meet a criteria (another form of an standing order) (Davis & Carr, 2015).  
  
Figure 37. Policies through with Naloxone in dispensed or prescribed by pharmacists in each of 
the fifty states (Naloxone access in community pharmacies. 2018) 
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One state that implemented a law allowing pharmacists to prescribe and dispense Naloxone 
to any individual at risk of an opioid overdose or their family members is Alabama. The state 
saw a 20% in the death rate due to opioid overdoes between 2013 and 2014 alone, placing 
Alabama as one the top five states with the highest increase in death from drug overdose. It is not 
surprising that this trend goes hand in hand with the fact that Alabamans are prescribed more 
opioids per person than any other state. Alabama passed House Bill 208 on June 3, 2015, this law 
allows physicians, pharmacists, and dentists to prescribe and dispense Naloxone and required 
documentation if the drug was for the individual at risk or their family and that they share 
information regarding the drug’s administration. Figure 38 shows the educational material the 
state used and distributed with Naloxone. One essential aspect of this bill is that it provided 
immunity to the prescribers and administrators.  About one year later Alabama expanded access 
to Naloxone even further by creating a statewide standing order, House Bill 379. This authorized 
all pharmacists to dispense naloxone without a prescription. Alabama’s initiatives to increase the 
access of Naloxone lead to the distribution of Naloxone take home kits and of equal importance 
increased community education (Wulz et al., 2017). 
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Figure 38. Educational information distributed to participants in Alabama’s Naloxone 
distribution program (Wulz et al., 2017). 
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 Figure 38. Continued (Wulz et al., 2017). 
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Of the states have adopted legislature to increase accesses to Naloxone for their citizens, 
emergency personnel, and vulnerable population New Mexico and Rhode Island are pioneers in 
this field. New Mexico was the first states to enact Good Samaritan Law protecting lay people 
from prosecution because they administer Naloxone in 2007. New Mexico is continuing to lead 
the way in in the fight against the opioid epidemic. They passed an innovative  law in April of 
2017 that expanded access of Naloxone by targeting people with the highest risk of an opioid 
overdose, people in opioid treatment programs, individuals who have been recently released 
from prison, and law enforcement officers who bear witness to many overdoses. The law does 
not stop with a free dose of Naloxone but is also accompanied by overdose education to every 
individual who receives the medication (Katzman et al., 2017).   New Mexico used evidence 
provided by countless researchers and institutions to target people most at risk and offer an 
effective and efficient route to combat the epidemic within their borders, in a proper meeting 
between public policy and academia. In Rhode Island, like many other states, opioid deaths are 
the leading cause of accidental deaths among adults. Rhode Island took a huge leap overcome the 
prescription status barrier that Naloxone faces. Rhode Island changed the status of the drug with 
in their state to an over the counter medication (Yokell et al., 2011). The originality is just 
beginning there. The state is developing and expanding a new program where Naloxone is placed 
in public areas just like a fire extinguisher or an Automatic External Defibrillator. One in ten 
overdoses in Rhode Island occurs in public and the NaloxBox (Figure 39) is bringing the 
lifesaving drug to the scene. The NaloxoBox is a box mounted on the walls of public spaces, 
such as public libraries, public transport stations, and other common areas. It allows individuals 
access to four doses of intranasal Naloxone, a mask to use with rescue breaths, and a short 
emergency ready informative pamphlet (Capraro & Rebola, 2018). 
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 There are many creative ideas that are contributing to lower the opioid associated death toll, 
most of which target people at risk of an overdose whether it be by their profession, past, or 
simply their location. There is another option as well, changing the way which opioids are 
prescribed. A common side effect of using an opioid is constipation and in anticipation anti-
constipation medications are typically prescribed along-side the opioid. Why not view an 
overdose as a side effect and accompany the opioid prescription with one for Naloxone? Thus, 
alerting the individuals of the danger of opioids and arming an at-risk population, those with 
opioid prescriptions with Naloxone. This would simply entail a campaign among providers, 
encouraging them to distribute Naloxone to their patients who are taking opioids. This would 
also create a steady market for the drug and could contribute to the stabilization or reverse the 
trend in rising cost.  
 
Figure 39. Example of a NaloxBox 
placed in a public library in Rhode Island. 
The box contains four doses of Naloxone, 
an educational pamphlet, and a mask used 
when delivering rescue breaths (Zalkind, 
2017). 
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 West Virginia has had notoriously high rate of opioid use and overdose death rates and as 
a result has been the focus of the media’s input of the opioid epidemic. The declining state of 
West Virginia’s economy, extremely high rates of poverty, and high proportion of people who 
live in rural areas (over 50%) are all contributing factors to the state’s status as the state with the 
highest per capita overdose rate of any state in the U.S.. Prescription opioids account for nine out    
of ten overdoses in West Virginia. The misuse of prescription opioids is not only illegal in the 
state but also highly persecuted. While there have been proposed and approved legislation to 
increase access to Naloxone, the progress the state has seen is marginal (Beheshti et al., 2015). 
The extent to which individuals are prosecuted, the degree of medicalization, and the attitude 
authorities have regarding opioids are holding progress back. The largest concern regarding 
increasing the availability of the drug is that individuals will be more likely to use an opioid or 
will use more when they have access to Naloxone, knowing that an overdose can be reversed. 
This concerns is unfounded as many studies have found that the rates of opioid use do not 
increase with access to Naloxone. For instance, one survey of heroin users found that less than 
35% reported that they would be more likely to use an opioid in Naloxone is available. West 
Virginia has passed a law allowing third party prescription, leading to the encouragement for the 
family members of users to carry and administer Naloxone (Beheshti et al., 2015). However, the 
potential of this law is drastically reduced by the stigma around opioid addiction. The efforts of 
West Virginia to combat the epidemic in their states has been limited by their unfounded concern 
and high degree of criminalization, causing progress to inch rather than bound forward.  
The United States is not the only country that has been subject to the wrath of an opioid 
epidemic. Countries such as the United Kingdom, Australia, Canada, and other European 
countries have also seen increases in the rates of opioid use and opioid related death. The high 
74 
 
 
prevalence of chronic pain in Canada is similar to that of the United States. While the use of 
opioids for noncancer chronic pain has not been pushed in Canada as strongly as it has in the 
U.S. because of Canada’s lower prescription rates of 22% the elevated rates of chronic pain are 
contributing to Canada’s opioid epidemic. (Moulin et al., 2002).  Australia is face to face with a 
potential epidemic of similar scale to the United States. As a result, the country has been pushing 
the use of take-home Naloxone kits as a cost-effective method to reduce the harms of opioids. 
The programs are similar to ones found in the United States in that individuals at risk of an 
overdose or likely to witness an overdose are issued Naloxone kits and educated about proper 
use and overdose identification. Australia faces many of the same barriers that the U.S. does 
including the rising cost of Naloxone, legal repercussions for opioid use, and the stigma that 
follows opioid addiction. However, unlike in the United States Naloxone is an over the counter 
medication in Australia as of February 2016 and each individual purchasing Naloxone receives 
education. Just as in the U.S the expansion of Naloxone access is key to reduce the death 
associated with nation-wide opioid addiction.  
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Conclusion 
 
The sociological aspects of the opioid epidemic bring light to the roots of the 
circumstances and the people that are being affected the most by this issue. Opioid use has 
cycled continuously across American history, peaking in the 1890’s and in the present day. The 
current grasp opioids have over this country began as form the corruption of a business. The 
efforts of Perdue Pharma to promote their new drug OxyContin in the 1980 intimately lead to a 
falsely founded paper and the immoral persuasion of physicians to use the product. This was 
done through false evidence and the pressure of large political movements, primarily the “Pain is 
the Fifth Vital Sign” movement. These movements were led by powerful organizations within 
the world of health care, most notably the Joint Commission, but were puppets at the hands of 
pharmaceutical companies.  
Their efforts caused number of prescriptions written for opioids to skyrocket. These 
prescriptions have been followed by addiction with suffering, poverty, and judicial action in its 
wake. This trend also means that the majority of opioid addiction are rooted in a prescription and 
are commonly among people with a medical condition, especially chronic pain. These people are 
more likely to commit suicide as because of their physical and mental anguish. Their opioid 
prescription offers an opportunity to intentionally overdose and end their lives, creating a bridge 
between opioid abuse rates and suicide rates. The use of heroin has also increased as a result of 
the opioid epidemic. Many people begin using opioids when the cost of prescription or opioids 
sold illegally becomes too large of a burden to bear and heroin offer a less expensive option. 
Individuals also turn to heroin when their prescription has expired, or their physician will no 
longer refill it. Forcing victims of the system deeper and deeper into an large scale and  
insurmountable cycle of addiction.  
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 The opioid epidemic follows many patterns within the populations that when combined 
put most people in an “at risk” category. Generational differences in opioid use put middle- aged 
people at the highest risk of opioid addiction. White people have the highest rate of opioid use 
followed by Native Americans. Minorities face opioid addiction as a consequence of  already 
difficult history and present reality facing minority people within American society, such as the 
high rate of poverty and the decreased access to health care. This is exemplified by the 
population of Native Americans. White opioid addicts are separated based on their economic 
class. Where upper class individuals are viewed as ill while lower class individuals are seen as 
criminals. There is also a regional trend in the epidemic which was shifted from the south 
western part of the country to the eastern area. The regional differences are attributed to the 
practices of health care found there. Areas with higher prescription rates correspond of regions 
with higher rates of opioid addiction.  
 There are many obstacles preventing the progress and increasing the use of Naloxone and 
other opioid treatment options. These include the stigma surrounding opioid use. Public opinion 
is contradictory in that many people view addiction as  a disease and as an issue to be resolved 
through medicine instead of legal action, but few acknowledge the role of stigma. Opioid addicts 
are still viewed as criminals, with the exception of the fortunate few who holding the white and 
wealthy status.  
Naloxone’s structure and chemical nature facilitate the action it takes within the body. 
The multiring molecule is composed of tetrahydrofuran ring, phenol, a cyclohexane, and a 
reactive ketone group. The structures of Naloxone and both natural and synthetic opioids are 
very similar. For instance, the only difference between Naloxone and morphine is an allyl group 
instead of a N- methyl group of morphine. Like many other drugs, Naloxone is most efficiently 
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created using a semi-synthesis technique. This process entails modifying a starting molecule to 
convert it into the desired product instead of building the molecule piece by piece form the 
ground up. The creation of Naloxone is an elegant use of semi synthesis along with several other 
basic tools in organic chemistry including protecting groups, the Grignard reagent, and the 
Burgess reagent.  
 The similarity between naloxone’s structure to that of opioids means that naloxone acts 
of similar regions and pathways in the brain. At a cellular level, natural and synthetic opioids are 
taken into different regions of the brain, where synthetic opioids are taken into the neurons 
through the use of transport vesicles. Both endogenous and synthetic opioids cause an increase in 
dopamine. The neurotransmitter associated with motivation and is a key component of reward- 
motivated behavior and is crucial in the formation of addiction.  
The danger in opioid lies in the drugs ability to reduce and stop respiration. Naloxone’s 
characteristics as an opioid antagonist are responsibility for its ability to stop an opioid overdose. 
The drug works by kicking off the opioid off the receptor, most commonly the µ receptor. 
Naloxone takes the place of the opioid and thus prevents the detrimental effects of the opioid. 
This extremely simple biochemical action is responsible for the lives of thousands of people.  
 Even though Naloxone is an effective at halting an opioid overdose the drug is not 
without its drawbacks. The largest issue with the drug is that people who are overdosing and 
have been administered Naloxone they are in danger of a relapsing overdose. Naloxone’s nature 
does not allow it to indefinitely bind to the opioid receptors in the brain. This means that if the 
when naloxone falls off the receptor an opioid molecule can replace it. When enough opioid 
receptors are occupied by and opioid the individual will have a second overdose. There is 
potential for this event to occur when the opioid has a longer half-life than Naloxone (it will last 
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longer than Naloxone), when the concentration of the opioid is significantly higher than that of 
Naloxone, or when the opioid has a higher affinity for the receptor than Naloxone. Fentanyl is a 
very hazardous drug because of its high affinity for the receptors, in many cases Naloxone may 
not be able to bind to the µ receptor or only has a very short interaction because of the high 
affinity of fentanyl.  This “after shock” overdose is especially dangerous when patients refuse 
medical care and to go to a hospital after they receive Naloxone. Many people are revived, feel 
perfectly healthy, refuse to be taken to the hospital by EMTs and die shortly later of a subsequent 
overdose.  
The creation of easily administered routes has greatly impacted the ability of the drug to 
enter the public and be placed in the hands of everyday people. The largest barrier to the 
distribution to the public lies in its status as a prescription medication. However, in recent years 
action had been taken to get around this factor. Some states have created state wide medical 
standing medical orders, standing orders involving the partnership of physicians and 
pharmacists, the creation of laws that allow pharmacists to dispense the drug without a 
prescription or even altering the prescription status of the drug. Health care providers hesitant of 
these efforts are concerned about legal prosecution. They are mainly concerned with allowing a 
third party to act a health care provider by administering the drug. The introduction of good 
Samaritan laws has curbed these concerns. These laws laymen to administer Naloxone and are 
rooted in the east to which Naloxone can be administer intranasally or intramuscularly.  
Allowing first responders to carry and administer Naloxone has also been a step in the right 
direction. Both police officers and EMTs are now permitted to give Naloxone where previously 
only paramedics were able.  
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 As the demand and use of Naloxone increases across the country so is the price tag. The 
name band and generic versions of the drug are produced by only one company. For instance, the 
company Adapt produces Narcan ®, the name brand nasal spray version of Naloxone. The price 
tag for products like Narcan ® have skyrocketed with those of the generic versions not too far 
behind. Ideas to stop the rising prices include concepts based upon increasing competition 
between companies  and government involvement to create a stable market for the drug. 
Lowering or maintaining the price of Naloxone is essential for the drugs availability to the 
public. Rising prices will make is particularly difficult for community Naloxone programs to 
continue. These programs have been widely successful at reducing opioid related deaths and 
work by distributing Naloxone and educating people, they mostly target the loved ones of opioid 
users. The rising prices make it more difficult for such programs to stay afloat. However, 
naloxone continues to be a cost effective as it remains well below the standardized $50,000 per 
quality- adjusted life year.  
 The legislation regulating Naloxone are being created at the state level, with some states 
paving the way and taking large steps to increase access and availability of Naloxone and others 
far behind them. New Mexico also recently passed new law where people at risk of opioid 
addiction and overdose are targeted for education and treatment. People who have been recently 
released from prison are one of the main focuses of this law. Rhode Island altered the status of 
the drug, so people no longer require a prescription to obtain Naloxone and created the NoxBox. 
Other states such as West Virginia are struggling with the opioid crisis but continue to have more 
restricted access to the lifesaving drug. The United States is not the only country facing this 
issue. Countries such as Australia, Canada and the United Kingdom are also confronted with the 
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issue. Australia for example, is facing an epidemic of similar scale to the U.S. if they do not take 
action. 
 In many ways we are at a tipping point in this country regarding the opioid crisis. If 
actions are taken to reduce unnecessary prescribing of the drug, increase addiction treatment 
options, and increase the access to the Naloxone the tides can change, and opioid related death 
can be reduced on a massive scale. Bigger boats take longer to turn around and it will take a 
substantial amount of time before we are no longer suffering the effects of the epidemic. These 
changes will undoubtably bring concerns and questions to the table. How will pharmaceutical 
companies react to the changes? What about insurance companies? Will they cover they 
addiction treatment? Will the population demographic continue to shift and change? What 
alternatives will heath care providers have for pain management and are they effective? 
Regardless of what happens the facts do not change, Naloxone saves lives. We are past a 
prevention stage and are in the trenches of the opioid epidemic. Naloxone is without a doubt the 
best option we have to preserve life in the midst of this crisis. Furthermore, Naloxone is key to 
keeping the epidemic at bay while alternative pain treatments and changes in prescribing trends 
alter the pattern the U.S is stuck in. Increasing the access this chemically elegant and effective 
drug will undoubtedly positively impact this country person by person and family by family in 
the fight again unnecessary death. 
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